Found: 166
Select item for more details and to access through your institution.
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.
- Published in:
- British Journal of Haematology, 1999, v. 107, n. 1, p. 121, doi. 10.1046/j.1365-2141.1999.01685.x
- By:
- Publication type:
- Article
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 1, p. 200, doi. 10.1007/s10637-012-9845-3
- By:
- Publication type:
- Article
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1121, doi. 10.1007/s10637-011-9670-0
- By:
- Publication type:
- Article
The DAC system and associations with multiple myeloma.
- Published in:
- Investigational New Drugs, 2010, v. 28, p. 28, doi. 10.1007/s10637-010-9589-x
- By:
- Publication type:
- Article
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 700, doi. 10.1002/ajh.26507
- By:
- Publication type:
- Article
Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E113, doi. 10.1002/ajh.26450
- By:
- Publication type:
- Article
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 896, doi. 10.1002/ajh.26263
- By:
- Publication type:
- Article
Authors' Response.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 8, p. 146, doi. 10.1002/ajh.24079
- By:
- Publication type:
- Article
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 4, p. 314, doi. 10.1002/ajh.23933
- By:
- Publication type:
- Article
Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 4, p. 290, doi. 10.1002/ajh.21613
- By:
- Publication type:
- Article
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 3, p. 149, doi. 10.1002/ajh.21340
- By:
- Publication type:
- Article
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
- Published in:
- American Journal of Hematology, 2005, v. 78, n. 4, p. 302, doi. 10.1002/ajh.20283
- By:
- Publication type:
- Article
Bortezomib is an efficient agent in plasma cell leukemias.
- Published in:
- International Journal of Cancer, 2005, v. 114, n. 4, p. 665, doi. 10.1002/ijc.20793
- By:
- Publication type:
- Article
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 6, p. 494, doi. 10.1111/ejh.13231
- By:
- Publication type:
- Article
Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 6, p. 352
- By:
- Publication type:
- Article
Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 9, p. 573
- By:
- Publication type:
- Article
Prognostic Impact of Pretransplantation Computed Tomography and Gallium Scans in Patients with Hodgkin Lymphoma with Poor Prognosis Undergoing Hematopoietic Stem Cell Transplantation.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 3, p. 217
- By:
- Publication type:
- Article
Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 60, n. 3, p. 332, doi. 10.1016/S0009-9236(97)90148-X
- By:
- Publication type:
- Article
Corrigendum: A fast and unbiased procedure to randomize ecological binary matrices with fixed row and column totals.
- Published in:
- Nature Communications, 2016, v. 7, n. 10, p. 13086, doi. 10.1038/ncomms13086
- By:
- Publication type:
- Article
Corrigendum: A fast and unbiased procedure to randomize ecological binary matrices with fixed row and column totals.
- Published in:
- Nature Communications, 2015, v. 6, n. 12, p. 10226, doi. 10.1038/ncomms10226
- By:
- Publication type:
- Article
A fast and unbiased procedure to randomize ecological binary matrices with fixed row and column totals.
- Published in:
- Nature Communications, 2014, v. 5, n. 6, p. 4114, doi. 10.1038/ncomms5114
- By:
- Publication type:
- Article
Analysis of Methylation Pattern in Multiple Myeloma.
- Published in:
- Acta Haematologica, 2005, v. 114, p. 23, doi. 10.1159/000087041
- By:
- Publication type:
- Article
Immunologic monitoring in adults with acute lymphoblastic leukemia.
- Published in:
- Current Oncology Reports, 2003, v. 5, n. 5, p. 413, doi. 10.1007/s11912-003-0028-4
- By:
- Publication type:
- Article
11 C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18 F-FDG PET/CT and Prognostic Value.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 17, p. 9895, doi. 10.3390/ijms23179895
- By:
- Publication type:
- Article
Two new 3′ PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia.
- Published in:
- Genes, Chromosomes & Cancer, 2000, v. 27, n. 1, p. 35, doi. 10.1002/(SICI)1098-2264(200001)27:1<35::AID-GCC5>3.0.CO;2-W
- By:
- Publication type:
- Article
Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia.
- Published in:
- American Journal of Hematology, 1999, v. 60, n. 3, p. 191, doi. 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y
- By:
- Publication type:
- Article
Chronic Graft-Versus-Host Disease: Pathogenesis and Clinical Management.
- Published in:
- Drugs, 2006, v. 66, n. 8, p. 1041
- By:
- Publication type:
- Article
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 350, doi. 10.1016/j.clml.2024.03.005
- By:
- Publication type:
- Article
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
- By:
- Publication type:
- Article
Disease Monitoring In Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 4, p. 244, doi. 10.1016/j.clml.2023.01.005
- By:
- Publication type:
- Article
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Corrigendum to "OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT" [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 425, doi. 10.1016/j.clml.2022.03.010
- By:
- Publication type:
- Article
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S163, doi. 10.1016/S2152-2650(21)02351-X
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S134, doi. 10.1016/S2152-2650(21)02305-3
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0
- By:
- Publication type:
- Article
Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01572-X
- By:
- Publication type:
- Article
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Micro-Environment (TIME) of Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e97, doi. 10.1016/j.clml.2019.09.159
- By:
- Publication type:
- Article
FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e94, doi. 10.1016/j.clml.2019.09.153
- By:
- Publication type:
- Article
Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e47, doi. 10.1016/j.clml.2019.09.071
- By:
- Publication type:
- Article
Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e32, doi. 10.1016/j.clml.2019.09.048
- By:
- Publication type:
- Article
Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e16, doi. 10.1016/j.clml.2019.09.023
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
- By:
- Publication type:
- Article
Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e1, doi. 10.1016/j.clml.2019.09.002
- By:
- Publication type:
- Article